127 related articles for article (PubMed ID: 2146258)
1. Characterization of thrombin- and plasmin-resistant mutants of recombinant human single chain urokinase-type plasminogen activator.
Eguchi Y; Sakata Y; Matsuda M; Osada H; Numao N; Ohmori M; Kondo K
J Biochem; 1990 Jul; 108(1):72-9. PubMed ID: 2146258
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of recombinant human single-chain urokinase-type plasminogen activator variants resistant to plasmin and thrombin.
Miyake T; Hibino Y; Kobayashi Y; Yokoyama M; Watabe K; Ohmori M
J Biochem; 1988 Oct; 104(4):643-7. PubMed ID: 2977134
[TBL] [Abstract][Full Text] [Related]
4. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
6. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
[TBL] [Abstract][Full Text] [Related]
7. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
[TBL] [Abstract][Full Text] [Related]
8. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Apr; 262(12):5682-9. PubMed ID: 3106341
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
Gurewich V; Pannell R; Broeze RJ; Mao J
J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
[TBL] [Abstract][Full Text] [Related]
11. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
[TBL] [Abstract][Full Text] [Related]
12. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
Fleury V; Lijnen HR; Anglés-Cano E
J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
15. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
Lijnen HR; Van Hoef B; Nelles L; Collen D
J Biol Chem; 1990 Mar; 265(9):5232-6. PubMed ID: 1969415
[TBL] [Abstract][Full Text] [Related]
18. Design and evaluation of a thrombin-activable plasminogen activator.
Yang WP; Goldstein J; Procyk R; Matsueda GR; Shaw SY
Biochemistry; 1994 Mar; 33(8):p606-12. PubMed ID: 8117652
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.
Gurewich V; Pannell R
Blood; 1987 Mar; 69(3):769-72. PubMed ID: 2949785
[TBL] [Abstract][Full Text] [Related]
20. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
Lourenço DM; Dosne AM; Kher A; Samama M
Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
